Biotech News
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection Phase 3 C-FORWARD Trial for HCV on Track for Topline Results in Early 2027 Phase 1 Trial Evaluating AT-587 as Potential
